Robust project management is essential in any manufacturing business, particularly where strict regulations and complex ...

Aviva’s in-house capital unit that invests in a range of infrastructure and real estate projects, and mixed-use developer ...

Clinigen, the global specialist pharmaceutical services group, today announced the appointment of Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). Reporting to the ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic ...

Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), today announced that it has completed its first life cycle assessment (LCA) for its market-leading BK357 ...

Aspira Women's Health Submits the Third Milestone of ARPA-H $10 Million Award  AUSTIN, TX / ACCESS Newswire / May 1, 2025 / Aspira Women's Health Inc. ("Aspira") (OTC PINK:AWHL), a bio-analytical ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team ...

Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a ...

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of ...

Acquisitions are On Track and Progressing From Signing to Closing; Guidance of $65M+ In Pro Forma Revenues Remains In PlaceTRNR Expects to Provide Positive Update on Sportstech Q1 2025 Performance in ...

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its preliminary unaudited ...

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ...